Discovery of ruthenium(ii) metallocompound and olaparib synergy for cancer combination therapy
Synergistic drug combinations can extend the use of poly(ADP-ribose) polymerase inhibitors (PARPi) such as Olaparib to BRCA-proficient tumors and overcome acquired or de novo drug resistance. To identify new synergistic combinations for PARPi, we screened a “micro-library” comprising a mix of commer...
| Päätekijät: | , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
American Chemical Society
2023
|
| Linkit: | http://psasir.upm.edu.my/id/eprint/107358/1/107358.pdf |